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for treatment of vulval intraepithelial neoplasia (RT³VIN): 
a multicentre, open-label, randomised, phase 2 trial
Amanda Tristram*, Christopher N Hurt*, Tracie Madden, Ned Powell, Stephen Man, Sam Hibbitts, Peter Dutton, Sadie Jones, Andrew J Nordin, 
Raj Naik, Alison Fiander†, Gareth Griﬃ  ths†
Summary
Background Vulval intraepithelial neoplasia is a skin disorder aﬀ ecting the vulva that, if left untreated, can become 
cancerous. Currently, the standard treatment for patients with vulval intraepithelial neoplasia is surgery, but this 
approach does not guarantee cure and can be disﬁ guring, causing physical and psychological problems, particularly 
in women of reproductive age. We aimed to assess the activity, safety, and feasibility of two topical treatments—
cidofovir and imiquimod—as an alternative to surgery in female patients with vulval intraepithelial neoplasia.
Methods We recruited female patients (age 16 years or older) from 32 centres to an open-label, randomised, phase 2 
trial. Eligibility criteria were biopsy-proven vulval intraepithelial neoplasia grade 3 and at least one lesion that could be 
measured accurately. We randomly allocated patients to topical treatment with either 1% cidofovir (supplied as a gel 
in a 10 g tube, to last 6 weeks) or 5% imiquimod (one 250 mg sachet for every application), to be self-applied three times 
a week for a maximum of 24 weeks. Randomisation (1:1) was done by stratiﬁ ed minimisation via a central computerised 
system, with stratiﬁ cation by hospital, disease focality, and presentation stage. The primary endpoint was a 
histologically conﬁ rmed complete response at the post-treatment assessment visit 6 weeks after the end of treatment 
(a maximum of 30 weeks after treatment started). Analysis of the primary endpoint was by intention to treat. 
Secondary outcomes were toxic eﬀ ects (to assess safety) and adherence to treatment (to assess feasibility). We present 
results after all patients had reached the primary endpoint assessment point at 6 weeks; 2-year follow-up of complete 
responders continues. This trial is registered with Current Controlled Trials, ISRCTN 34420460.
Findings Between Oct 21, 2009, and Jan 11, 2013, 180 participants were enrolled to the study; 89 patients were randomly 
allocated cidofovir and 91 were assigned imiquimod. At the post-treatment assessment visit, a complete response had 
been achieved by 41 (46%; 90% CI 37·0–55·3) patients allocated cidofovir and by 42 (46%; 37·2–55·3) patients 
assigned imiquimod. After 6 weeks of treatment, 156 (87%) patients (78 in each group) had adhered to the treatment 
regimen. Five patients in the cidofovir group and seven in the imiquimod group either withdrew or were lost to 
follow-up before the ﬁ rst 6-week safety assessment. Adverse events of grade 3 or higher were reported in 31 (37%) of 
84 patients allocated cidofovir and 39 (46%) of 84 patients assigned imiquimod; the most frequent grade 3 and 4 
events were pain in the vulva, pruritus, fatigue, and headache.
Interpretation Cidofovir and imiquimod were active, safe, and feasible for treatment of vulval intraepithelial neoplasia 
and warrant further investigation in a phase 3 setting. Both drugs are eﬀ ective alternatives to surgery for female patients 
with vulval intraepithelial neoplasia after exclusion of occult invasive disease.
Funding Cancer Research UK.
Copyright © Tristram et al. Open Access article distributed under the terms of CC BY.
Introduction
Vulval intraepithelial neoplasia is a chronic pre malignant 
disorder that aﬀ ects the vulval skin. The age-standardised 
incidence is about one case per 100 000 women per year, 
with a peak at 30–49 years of age, and incidence has been 
rising over recent decades.1,2 Vulval intraepithelial neoplasia 
is graded as 1, 2, or 3 according to the proportion of the 
epithelium containing undiﬀ erentiated cells, with grade 3 
disease showing full thickness neoplasia.3 Symptoms can 
be severe and include pain, itching, and dyspareunia, with 
treatment generally needed on these grounds alone.4 
The disorder might be related to lichen sclerosus.5
More than 80% of women with vulval intraepithelial 
neoplasia have lesions associated with high-risk types of 
human papillomavirus (HPV), most typically HPV type 16. 
Persistent infection with high-risk types of HPV typically 
precedes deregulation of viral gene expression, leading to 
increased amounts of E6 and E7 oncoproteins and 
resulting in loss of activity of the tumour-suppressor 
proteins P53 and Rb, respectively. The rate of progression 
to invasive disease is diﬃ  cult to estimate, because most 
patients undergo surgery to remove lesions, but it can be 
up to 5% per year, or 1–2% a year with surgery.6 
Spontaneous regression happens in 1·2% of patients and 
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usually takes place within the ﬁ rst 10 months.6 Surgery 
(either excision or ablation) is the standard treatment, but 
this approach can be associated with substantial 
morbidity,4,7 and recurrence is high (30–60%).8
Alternatives to surgery for vulval intraepithelial 
neoplasia are needed, and topical drugs and systemic 
treatments (eg, photodynamic therapy and immuno-
therapy) have been investigated. Two candidate drugs 
identiﬁ ed for topical use are cidofovir and imiquimod. 
Cidofovir is a nucleoside analogue with antiviral 
properties and proven activity in comparable disease 
(cervical intraepithelial neoplasia). In a pilot study of 
15 women with cervical intraepithelial neoplasia type 3, 
seven (47%) of 15 women had a complete response 
after topical application of the drug.9 In a pilot study of 
cidofovir for vulval intraepithelial neoplasia grade 3, 
four (40%) of ten women had a complete response at the 
end of follow-up.10 Imiquimod is a drug that modiﬁ es 
the immune response. In previous small studies of 
topical imiquimod (n≤15), a complete response was 
reported in 28 (41%) of 67 women with vulval intra-
epithelial neoplasia, but with substantial variation 
among studies (0–73%).11–16
We aimed to assess the activity, safety, and feasibility of 
cidofovir and imiquimod in the Randomised Trial of 
Topical Treatment in Women with Vulval Intraepithelial 
Neoplasia (RT³VIN), an open-label, randomised phase 2 
trial developed in the UK on behalf of the UK’s National 
Cancer Research Institute.
Methods
Study design and patients
We did an open-label, randomised phase 2 trial at 
32 teaching and general hospitals located in Wales and 
England (appendix p 3). We included female patients who 
were age 16 years or older, had biopsy-proven vulval 
intraepithelial neoplasia grade 3 (including visible peri-
anal disease not extending into the anal canal) within the 
past 3 months, and had at least one lesion that could be 
measured accurately with either a longest diameter of at 
least 20 mm or an area greater than 120 mm² (ascertained 
by measurement of two perpendicular dimensions). 
About halfway through recruitment (Sept 28, 2011), 
we expanded the inclusion criterion for size of lesion 
from “at least one lesion with longest diameter of at least 
20 mm” to that described, to allow more patients to be 
entered into the study while ensuring that all lesions 
would be of suﬃ  cient size to allow a biopsy specimen to 
be taken. Clinicians with a special interest in vulval 
intraepithelial neoplasia recruited the participants.
We excluded early invasive disease by clinical and 
vulvoscopic examination (and, if necessary, biopsy), 
which was done by skilled clinicians. We also excluded 
pregnant women (by measurement of human chorionic 
gonadotropin in urine) and patients with impaired renal 
function (deﬁ ned as serum creatinine >133 μmol/L). 
Moreover, we excluded individuals who had received 
active treatment for vulval intraepithelial neoplasia 
within the previous 4 weeks or who had a recorded failure 
on imiquimod or cidofovir after treatment three times a 
week for a minimum of 12 weeks. Finally, we excluded 
individuals with a known allergy to either of the topical 
treatments or any of their components.
All patients provided written informed consent before 
randomisation. We obtained appropriate regulatory 
approval from the UK Medicines and Healthcare 
Products Regulatory Agency (21323/0020/001-0001), the 
Oﬃ  ce for Research Ethics Committees Northern Ireland 
(08/NIR03/82), and NHS research and development 
departments at participating sites.
Randomisation and masking
We randomly allocated patients in a 1:1 ratio to topical 
treatment with either imiquimod or cidofovir via a 
89 allocated cidofovir 91 allocated imiquimod 
89 allocated cidofovir analysed for 
       primary endpoint (intention-to-treat) 
91 allocated imiquimod analysed for 
      primary endpoint (intention-to-treat) 
17 discontinued treatment 
 3 lost to follow-up 
 12 withdrew from treatment 
  (10 intolerance or patient’s 
  choice, 2 clinician’s choice 
  because of complications) 
 2 invalid biopsy specimen or 
  biopsy not done 
22 discontinued treatment 
 5 lost to follow-up 
 15 withdrew from treatment 
  (15 intolerance or patient’s 
  choice)
 2 invalid biopsy specimen or 
  biopsy not done
72 allocated cidofovir included in 
      per-protocol analyses 
69 allocated imiquimod included in 
       per-protocol analyses
18 eligible to crossover to imiquimod 14 eligible to crossover to cidofovir
11 crossed over to cidofovir 12 crossed over to imiquimod 
514 assessed for eligibility
332 excluded 
 228 did not meet inclusion criteria 
 72 declined to participate (55 wanted surgery, 
  17 other reasons)
 13 had used imiquimod before
 19 other reasons
182 enrolled 
2 excluded after enrolment (did not meet inclusion criteria)
180 underwent randomisation
Figure: Trial proﬁ le
See Online for appendix
For the protocol of this trial see 
http://www.wctu.org.uk/rt3vin/
FINAL%20Signed%20
Protocol%20Version%205.0%20
18082011.pdf
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central computerised system by stratiﬁ ed minimisation 
(with an 80:20 random element). We stratiﬁ ed the 
randomisation by hospital, unifocal or multifocal disease, 
and ﬁ rst presentation or recurrent disease. The study had 
an open-label design so we did not mask the treatment 
allocation from patients or investigators. Furthermore, 
masking was not possible because cidofovir gel has a 
very diﬀ erent appearance from imiquimod.
Procedures
A licensed pharmaceutical unit (St Mary’s Pharmaceutical 
Unit [SMPU], Cardiﬀ  & Vale University Health Board) 
converted commercially available intravenous cidofovir 
into 1% topical gel (the same concentration as used in the 
pilot study),10 which was supplied to recruiting centres in 
10 g tubes. We asked patients allocated cidofovir to spread 
a thin layer of the gel over the whole aﬀ ected area three 
times a week for a maximum of 24 weeks, with every 10 g 
tube to last about 6 weeks, requiring four tubes in total. 
We used commercially available sachets of 5% 
imiquimod. We asked patients assigned imiquimod to 
spread the contents of one sachet (250 mg) over the 
whole aﬀ ected area three times a week for a maximum of 
24 weeks, requiring 72 sachets in total. We advised 
patients to apply the treatment at night and wash with 
aqueous cream and water the next day.
If the patient was unable to tolerate three applications 
per week, we allowed them to reduce the dosage by 
one application a week, then two applications if 
intolerance continued. We stopped treatment if more 
than six consecutive applications were missed or if 
serum creatinine was more than 133 μmol/L. If new 
lesions arose during the trial they were also treated, but 
we did not include them in the assessments.
At baseline, we recorded the patient’s medical history, 
did a clinical assessment of the lesion with adapted 
Response Evaluation Criteria in Solid Tumors (RECIST; 
appendix pp 1–2), did a pregnancy test, assessed toxic 
eﬀ ects with the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events (CTCAE) 
version 3.0, analysed urine for protein, and did a 4 mm 
punch biopsy for HPV testing. We marked lesions 
present at baseline on a case report form (CRF) and 
recorded on the CRF the lesion from which the diagnostic 
biopsy specimen was taken. We speciﬁ cally sought 
details about other previous anogenital neoplasia and 
whether the patient was immunocompromised.
We analysed biopsy samples taken at baseline for the 
presence of HPV 16, using type-speciﬁ c E6 PCR.17 
To detect non-HPV 16 types, we also tested all samples 
with the Greiner PapilloCheck assay (Greiner Bio-One, 
Frickenhausen, Germany), a PCR-based assay designed 
to detect 18 high-risk HPV types.
We assessed patients at 6, 12, 18, and 24 weeks of 
treatment. We did a clinical assessment of the lesion 
using adapted RECIST, did a pregnancy test, and 
analysed a urine sample. Furthermore, we assessed 
adherence to treatment by collection of diary cards and 
we recorded toxic eﬀ ects (deﬁ ned by CTCAE version 3.0). 
Reporting of serious adverse events was real-time until 
30 days after the last participant received their last dose 
of treatment.
We asked patients to attend a post-treatment 
assessment visit either 6 weeks after the end of treatment 
(a maximum of 30 weeks after treatment started) or 
6 weeks after a complete response or disease progression 
Cidofovir
(n=89)
Imiquimod
(n=91)
Age (years) 48 (42–52) 46 (41–55)
Immunocompromised
Yes 3 (3%) 6 (7%)
No 86 (97%) 85 (93%)
Smoking status
Current 50 (56%) 56 (62%)
Previous 24 (27%) 18 (20%)
Never 15 (17%) 17 (19%)
Disease focality
Unifocal 44 (49%) 45 (49%)
Multifocal 45 (51%) 46 (51%)
Lesion size (mm)* 40 (30–60) 40 (30–65)
Time from current diagnosis of VIN 
to randomisation (days)
44 (21–73) 36 (16–73)
Recurrent VIN
Yes 42 (47%) 40 (44%)
No 47 (53%) 51 (56%)
Time from ﬁ rst diagnosis of VIN to 
randomisation (months)†
58·0
(19·8–114·8)
79·4
(22·0–117·8)
Number of previous treatments†
0 2 (2%) 6 (7%)
1 16 (18%) 11 (12%)
2–4 20 (22%) 19 (21%)
≥5 1 (1%) 4 (4%)
Unknown 3 (3%) 0
Previous other anogenital neoplasia
Cervical intraepithelial neoplasia 29 (33%) 23 (25%)
Vaginal intraepithelial neoplasia 6 (7%) 3 (3%)
Anal intraepithelial neoplasia 6 (7%) 5 (5%)
None 48 (54%) 59 (65%)
Unknown 0 1 (1%)
HPV DNA positive
Yes 75 (84%) 76 (84%)
No 8 (9%) 7 (8%)
Missing biopsy ﬁ ndings 6 (7%) 8 (9%)
HPV 16 DNA positive‡
Yes 68 (76%) 67 (74%)
No§ 15 (17%) 16 (18%)
Data are number of patients (%) or median (IQR). VIN=vulval intraepithelial 
neoplasia. *Sum of longest diameters. †Applicable to patients with recurrent 
disease only. ‡Applicable to patients who are HPV DNA positive. §Includes 
patients who are HPV DNA negative.
Table 1: Baseline characteristics
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(deﬁ ned by adapted RECIST). At the post-treatment 
assessment visit, we did the same tests as we did during 
the treatment stage. We also took two 4 mm biopsy 
specimens to assess histological response and for HPV 
testing, and we obtained blood samples for measurement 
of haemoglobin, white blood cell count, urea, and 
electrolytes. If more than one lesion was present, we took 
the biopsy specimen from the same lesion as the original 
diagnostic biopsy (and other lesions if judged clinically 
necessary). If no lesion was visible at the post-treatment 
assessment visit, we took a biopsy specimen from the 
same site as the original diagnostic biopsy.
We followed up patients who had a histological 
complete response at the post-treatment assessment visit 
every 6 months (at 6, 12, 18, and 24 months). We assessed 
toxic eﬀ ects, did a clinical examination, and if a lesion 
was present, we took a biopsy specimen for histological 
analysis. We also took blood samples at baseline, at 
6 weeks of treatment, and at the post-treatment 
assessment visit, and we banked these specimens for 
future translational research.
If a participant had a complete response or disease 
progression (deﬁ ned by adapted RECIST) at any time 
during the 24-week treatment stage, we stopped 
treatment and did the post-treatment assessment visit 
6 weeks later. Patients who had stable disease or disease 
progression (by adapted RECIST) at the post-treatment 
assessment visit, for whom invasive disease had been 
ruled out, were eligible for crossover to the alternate 
treatment for a maximum of 24 weeks. Subsequent 
management beyond the post-treatment assessment visit 
in patients without a complete response was at the 
discretion of the treating clinician.
Outcomes
The primary endpoint was a histologically conﬁ rmed 
complete response in baseline lesions at the post-treatment 
assessment visit (6 weeks after completion of treatment, a 
maximum of 30 weeks after the start of treatment). In this 
report, we present results from the point at which all 
patients had completed the primary endpoint. Secondary 
endpoints were adherence to the dosing regimen at 
6 weeks and 24 weeks during the treatment stage (to assess 
feasibility), toxic eﬀ ects during the 24-week treatment 
stage and at the post-treatment assessment visit (to assess 
safety), prediction of response according to HPV status, 
and the proportion of patients who had a recurrence 
(histologically conﬁ rmed vulval intraepithelial neoplasia 
grade 3) at 12 months.
Statistical analysis
The primary aim of the RT³VIN trial was to assess eﬃ  cacy 
of cidofovir and imiquimod in terms of the primary 
endpoint. We used a Fleming’s single-stage design in each 
treatment arm of the study to show eﬃ  cacy for cidofovir 
and imiquimod separately; the study was not formally 
powered to compare the complete response at 30 weeks 
between arms. If fewer than 30% of patients had had a 
complete response at 30 weeks in either treatment arm, 
the treatment would be deemed insuﬃ  ciently active to 
warrant further study; if, however, 45% or more patients 
had a complete response in either treatment arm, the 
treatment would be deemed worthy of further investi-
gation. With Fleming’s single-stage design, a p1 value of 
0·30 and a p2 value of 0·45, an α of 0·05 (one-sided), and 
90% power, we calculated that 87 participants needed to be 
assigned to each treatment group, giving a total of 
174 participants. We analysed data with Stata 13. 
For the primary endpoint, we analysed each treatment 
arm by both intention to treat (ie, including all patients 
randomly allocated to a group) and per protocol (ie, inclu-
ding all individuals who continued treat ment until 
Cidofovir (n=89) Imiquimod (n=91)
Grade 1–2 Grade 3 Grade 1–2 Grade 3
Expected adverse events
Fatigue 19 (21%) 3 (3%) 21 (23%) 4 (4%)
Pruritus 46 (52%) 3 (3%) 43 (47%) 6 (7%)
Ulceration 3 (3%) 0 6 (7%) 0
Pain in vulva 33 (37%) 2 (2%) 21 (23%) 1 (1%)
Headache 14 (16%) 1 (1%) 12 (13%) 3 (3%)
Muscle pain 11 (12%) 0 13 (14%) 0
Proteinuria 4 (4%) 0 9 (10%) 0
Other adverse events*
Neurological event 2 (2%) 0 2 (2%) 1 (1%)
Pulmonary or upper-respiratory event 0 1 (1%) 0 0
Data are number of patients (%). Adverse events deﬁ ned by Common Terminology Criteria of Adverse Events, 
version 3. No grade 4 adverse events were reported. *Included if at least one patient had an event of grade 3 or higher, 
or if grade 1–2 toxic eﬀ ects in more than 10% of the population were present in any column.
Table 2: Adverse events at baseline
Cidofovir (n=89) Imiquimod (n=91)
First 6 weeks of the study
Patients meeting 6-week adherence endpoint 78 (88%) 78 (86%)
Lost to follow-up 0 1
Withdrew from treatment (intolerance or patient’s choice) 5 6
Incomplete record card 6 6
Number of treatment applications 17 (16–18) 16 (14–18)
During the 24-week treatment stage
Patients with all four record cards completed* 50 (56%) 37 (41%)
Lost to follow-up 2 2
Withdrew from treatment (intolerance or patient’s choice) 10 15
Clinician stopped treatment because of complications 1 0
Stopped early, progression 6 7
Stopped early, complete response 10 18
Incomplete record card 10 12
Number of treatment applications 67·5 (64–71) 63·0 (50–67)
Data are number of patients (%) or median (IQR). *Record cards completed at 6, 12, 18, and 24 weeks.
Table 3: Treatment adherence and reasons for stopping treatment
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complete response, disease progression, or 24 weeks). 
In the intention-to-treat analysis, we regarded all patients 
without a biopsy specimen after treatment as failures. 
We recorded the number of patients with a histologically 
conﬁ rmed complete response at the post-treatment 
assessment visit in each treatment group and calculated 
the corresponding proportion; we used the Clopper-
Pearson exact binomial method to calculate the 90% CI 
for the proportion. To look for predictors of response in 
each treatment group, we did per-protocol subgroup 
analyses of the primary endpoint for several predeﬁ ned 
variables, using either Pearson’s χ² test or Fisher’s exact 
method (if any cell included fewer than ﬁ ve patients).
We assessed adherence to treatment at 6 weeks and 
24 weeks in terms of the median (IQR) number of 
applications during each period for all patients completing 
treatment (and treatment diary cards) up to those 
timepoints. We recorded the number of toxic eﬀ ects at 
baseline and in all patients who applied the assigned 
treatment at least once, in terms of the worst grade 
reported during treatment and at the post-treatment 
assessment visit, and we calculated proportions for each 
treatment group. We predeﬁ ned seven expected adverse 
events—ie, either symptoms of vulvar intra epithelial 
neoplasia or known toxic eﬀ ects of the drugs. These events 
were fatigue, pruritus, ulceration, pain in the vulva, 
headache, muscle pain, and proteinuria; we reported 
ﬁ ndings separately for these adverse events. We gathered 
data for other toxic eﬀ ects but grouped them into 
categories according to CTCAE version 3.0, for analyses.
As an exploratory analysis, we compared toxicity 
outcomes between arms, in patients who had applied the 
treatment at least once. For example, we compared 
between treatment arms the proportions of expected 
adverse events and of all toxic eﬀ ects of grade 2 or higher 
recorded during treatment, using Pearson’s χ² test. 
Also, we assessed the diﬀ erence in symptom scores from 
baseline to the post-treatment assessment visit for 
pruritus and vulval pain for each treatment arm, using 
McNemar’s test (and Fisher’s exact method if fewer than 
ﬁ ve patients were recorded in any cell). We also combined 
data for reported serious adverse events with toxic eﬀ ects 
recorded on CRFs.
This trial is registered with Current Controlled Trials, 
ISRCTN 34420460.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation of data, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Oct 21, 2009, and Jan 11, 2013, 180 patients were 
enrolled from 32 hospitals across the UK (appendix p 3); 
89 were randomly allocated to receive cidofovir and 
91 were assigned to receive imiquimod (ﬁ gure). Median 
age of participants was 47 years (IQR 41–54) and 148 (82%) 
had a history of smoking. Vulval intraepithelial neoplasia 
was recurrent in 82 (46%) individuals. Biopsy specimens 
Cidofovir (n=84) Imiquimod (n=84)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Expected adverse events
Fatigue 38 (45%) 13 (15%) 0 42 (50%) 19 (23%) 3 (4%)
Pruritus 59 (70%) 11 (13%) 0 62 (74%) 10 (12%) 0
Ulceration 37 (44%) 4 (5%) 0 31 (37%) 5 (6%) 0
Pain in vulva 49 (58%) 16 (19%) 0 57 (68%) 12 (14%) 1 (1%)
Headache 34 (40%) 3 (4%) 0 45 (54%) 9 (11%) 1 (1%)
Muscle pain 25 (30%) 2 (2%) 0 45 (54%) 4 (5%) 0
Proteinuria 19 (23%) 0 0 31 (37%) 1 (1%) 0
Other adverse events*
Constitutional symptoms 7 (8%) 0 0 4 (5%) 1 (1%) 0
Dermatological or skin event 14 (17%) 2 (2%) 0 13 (15%) 1 (1%) 0
Gastrointestinal event 6 (7%) 0 0 12 (14%) 0 0
Neurological event 4 (5%) 1 (1%) 0 12 (14%) 1 (1%) 0
Pain 22 (26%) 4 (5%) 2 (2%) 21 (25%) 1 (1%) 0
Inﬂ uenza-like symptoms 2 (2%) 2 (2%) 0 12 (14%) 1 (1%) 0
Data are number of patients (%). Adverse events were recorded in patients who applied the treatment at least once. 
Five (6%) of 89 patients assigned cidofovir and seven (8%) of 91 patients allocated imiquimod were lost to follow-up 
before the ﬁ rst assessment for toxic eﬀ ects and were excluded from this analysis. Adverse events were deﬁ ned by 
Common Terminology Criteria of Adverse Events, version 3. PTAV=post-treatment assessment visit. *Included if at 
least one patient had an event of grade 3 or higher, or if grade 1–2 toxic eﬀ ects in more than 10% of the population 
were present in any column.
Table 4: Adverse events during the 24-week treatment stage and at the PTAV
Cidofovir (n=72) Imiquimod (n=69)
Response at PTAV*
Complete response 41 (57%) [90% CI 47–67] 42 (61%)[90% CI 50–71]
Partial response 14 (19%) 10 (14%)
Stable disease 8 (11%) 6 (9%)
Disease progression 8 (11%) 10 (14%)
No RECIST measurement 1 (1%) 1 (1%)
Type of VIN at PTAV
VIN not present 41 (57%) 42 (61%)
VIN1 0 2 (3%)
VIN2 2 (3%) 3 (4%)
VIN3 25 (35%) 22 (32%)
Inconclusive 4 (6%) 0
Number of treatment applications in the ﬁ rst 6 weeks
In women with a complete response 17 (16–18) 17 (15–18)
In non-responders 17 (15–17) 16 (13–17)
Complete responders reaching 12-month follow-up 23/41 (56%) 32/42 (76%)
Complete response maintained at 12 months 20/23 (87%) 25/32 (78%)
Data are number of patients (%) or median (IQR), unless otherwise stated. 90% CI calculated with the Clopper-Pearson 
method. Per-protocol population includes all participants who continued treatment until complete response, disease 
progression, or 24 weeks. PTAV=post-treatment assessment visit. RECIST=Response Evaluation Criteria for Solid 
Tumors. VIN=vulval intraepithelial neoplasia. *Response assessed with adapted RECIST (appendix pp 1–2).
Table 5: Response of patients at the PTAV and characteristics of complete responders (per-protocol 
population)
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for HPV testing were obtained at baseline from 166 (92%) 
patients. High-risk HPV DNA was present in 151 (91%) of 
166 baseline biopsy specimens, of which 135 (89%) were 
HPV type 16. Baseline demographics, disease variables, 
and HPV characteristics were balanced between 
treatment groups (table 1), and adverse events at baseline 
(deﬁ ned by CTCAE version 3) were also similar (table 2).
Five (6%) of 89 patients allocated cidofovir and 
seven (8%) of 91 assigned imiquimod either withdrew 
or were lost to follow-up before the ﬁ rst 6-week 
assessment and were regarded as non-compliant with 
the protocol. Adherence to treatment was similar in 
each group at both 6 and 24 weeks, and the median 
number of treat ment applications by patients did not 
diﬀ er at these timepoints for either cidofovir or 
imiquimod (table 3). A further two patients in each 
group were lost to follow-up before 24 weeks and were 
regarded as non-compliant with the protocol. Treatment 
was stopped early because of intolerance in ten (11%; 
95% CI 5·7–20·1) of 87 patients allocated cidofovir and 
15 (17%; 9·8–26·3) of 89 assigned imiquimod. Ten (11%; 
2·7–20·1) of 87 patients assigned cidofovir had a 
complete response by 18 weeks and stopped treatment 
early, compared with 18 (20%; 12·4–30·1) of 
89 individuals allocated imiquimod.
Most adverse events recorded during the 24-week 
treatment stage or in the 6 weeks after treatment ended 
were grade 2 (table 4). Adverse events of grade 2 or 
higher were less frequent in patients assigned cidofovir 
compared with individuals allocated imiquimod 
(61 [73%] of 84 patients vs 73 [87%] of 84 patients; 
p=0·021). The main diﬀ erences between treatments 
with respect to toxic eﬀ ects of grade 2 or higher were 
fatigue, pruritus, and headache, which were all at least 
10% more frequent in the imiquimod arm (table 4). 
Toxic eﬀ ects of grade 3 or higher were similar between 
groups (31 [37%] of 84 patients allocated cidofovir vs 
39 [46%] of 84 patients assigned imiquimod; p=0·211). 
By per-protocol analysis, the propor tion of patients with 
pruritus grade 2 or higher fell signiﬁ cantly between 
baseline and the post-treatment assessment in both 
treatment groups (cidofovir, 14 [19%] of 72 patients vs 
ﬁ ve [7%] of 72 patients; p=0·013; imiquimod, 15 [22%] of 
69 patients vs ﬁ ve [7%] of 69 patients; p=0·008). 
No diﬀ erence in the proportion of patients with grade 2 
or higher vulval pain was seen between baseline and the 
post-treatment assessment (cidofovir, nine [13%] of 
72 patients vs three [4%] of 72 patients; p=0·109; 
imiquimod, four [6%] of 69 patients vs four [6%] of 
69 patients; p=1·000). No deaths were reported.
By intention-to-treat analysis, at the 6-week post-
treatment assessment visit, 41 (46%, 90% CI 37·0–55·3) 
of 89 patients allocated cidofovir had a complete 
response compared with 42 (46%, 37·2–55·3) of 91 
patients allocated imiquimod. This result was replicated 
by per-protocol analysis (table 5). New lesions arose 
during the 24-week treatment stage in 19 (21%) of 87 
patients assigned cidofovir and 11 (12%) of 91 patients 
allocated imiquimod; however, we do not know whether 
any of these new lesions arose within the treatment area 
or not. 
Table 6 presents the per-protocol analysis of predictors of 
treatment response. The presence of high-risk HPV DNA 
or HPV type 16 DNA did not predict response, nor did 
disease focality, recurrence of disease, or smoking status. 
In the per-protocol population, two patients allocated 
cidofovir had previously been immuno compromised: 
one responded to treatment and one did not. Six individuals 
assigned imiquimod had also been immunocompromised, 
of whom two responded and four did not.
23 patients crossed over to the alternative treatment 
(ﬁ gure), of whom 16 had a post-treatment biopsy sample 
taken. Three (43%) of seven patients who received 
cidofovir after crossover had a complete response 
compared with four (44%) of nine individuals who were 
given imiquimod after crossover.
Follow-up data for the 83 patients who had a complete 
response is not yet mature (median follow-up 
24·9 months [IQR 13·5–31·2]), but ﬁ ndings currently 
suggest that complete response (ie, absence of vulval 
intraepithelial neoplasia) is maintained at 12 months. 
At the time of this analysis, 20 (87%) of 23 patients 
assigned cidofovir still had a complete response at 
12-month follow-up, as did 25 (78%) of 32 individuals 
allocated imiquimod.
Cidofovir (n=72) Imiquimod (n=69)
Complete 
responders 
(n)
Non-
responders 
(n)
p Complete 
responders 
(n)
Non-
responders 
(n)
p
HPV status*
HPV DNA positive 31 28 .. 32 25 ..
HPV DNA negative 6 2 0·281† 6 1 0·225†
HPV 16 E6 DNA positive‡ 27 25 .. 26 23 ..
HPV 16 E6 DNA positive‡ 4 3 1·000† 6 2 0·444†
Disease focality
Unifocal 24 13 .. 20 13 ..
Multifocal 17 18 0·163 22 14 0·966
Disease recurrence
First presentation 22 17 .. 24 13 ..
Recurrent disease 19 14 0·921 18 14 0·465
Smoking status
Current smoker 24 15 .. 23 16 ..
Not current smoker 17 16 0·392 19 11 0·713
Immune status
Immunocompromised 1 1 .. 2 4 ..
Not immunocompromised 40 30 1·000† 40 23 0·201†
Data are number of patients. Per-protocol population includes all participants who continued treatment until 
complete response, disease progression, or 24 weeks. HPV=human papillomavirus. VIN=vulval intraepithelial 
neoplasia. *Data missing for ﬁ ve patients in each treatment group. †Exact; when fewer than ﬁ ve patients were 
analysed, p values were calculated with Fisher's exact method. ‡In patients who were HPV DNA positive.
Table 6: Subgroup analyses of complete responders versus non-responders (per-protocol population)
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Discussion
The ﬁ ndings of the RT³VIN trial show that both 
imiquimod and cidofovir are safe, active, and feasible for 
treatment of vulval intraepithelial neoplasia grade 3. 
Both treatments met the predeﬁ ned criteria for eﬃ  cacy, 
with complete responses in more than 45% of patients 
recorded by intention to treat. Adverse events were similar 
between treatments, although events of grade 2 or higher 
were more frequent in patients assigned imiquimod 
compared with those allocated cidofovir. Biomarkers 
related to demographics, disease charac teri stics, or viral 
status were not predictive of treatment response. As far as 
we know, our study is the largest to date to assess topical 
treatments for vulval intraepithelial neoplasia, with 
patients recruited from both teaching and general 
hospitals, supporting the relevance of these ﬁ ndings to 
general clinical practice (panel). Although cidofovir had 
slightly fewer reported toxic eﬀ ects, imiquimod is available 
for use and is an eﬀ ective alternative to surgery that can be 
oﬀ ered to women with vulval intraepithelial neoplasia 
after exclusion of occult invasive disease.
The International Society for the Study of Vulval Disease 
uses morphological criteria to classify vulval intraepithelial 
neoplasia into usual-type (HPV-related) or diﬀ erentiated 
(non-HPV-related). This classiﬁ cation was debated3 and, 
initially, not applied widely in the UK. In the RT³VIN trial, 
we wanted to use a deﬁ nition that was familiar to 
pathologists in the UK, provided a clear threshold for 
entry into the study, and minimised intra observer 
variability. Therefore, we used the previous classi ﬁ cation 
of vulval intraepithelial neoplasia grades 1–3, and we 
chose grade 3 disease for our entry criteria. This system 
does not attribute disease origin by histological 
appearances; instead, HPV testing was undertaken on all 
samples to establish the cause of disease. An alternative 
approach would have been to record clinical evidence of 
vulval dermatoses such as lichen sclerosus. The primary 
endpoint of the RT³VIN trial was a complete response—
ie, no evidence of any vulval intraepithelial neoplasia on 
histological analysis, which also minimised intraobserver 
variability. We considered central histo logical review, but 
that would have caused substantial logistical diﬃ  culties in 
an already challenging trial.
Table 3 shows that the primary reason for exclusion from 
the per-protocol analysis was withdrawal from treatment 
because of intolerance or by patient’s choice. All exclusions 
were regarded as treatment failures in the intention-to-
treat analysis; therefore, our results represent a worst-case 
scenario. Data for adherence to treatment tailed oﬀ  after 
the ﬁ rst 6 weeks of the study; however, before this 
timepoint, data collection was good (around 86%) and 
response to treatment did not seem to be related to 
adherence. Although the RT³VIN trial was randomised, 
the Fleming’s design is not aimed primarily at direct 
comparison between arms; thus, the study was not 
powered to detect a diﬀ erence in eﬃ  cacy between cidofovir 
and imiquimod. More adverse events were noted with 
imiquimod than with cidofovir, but most were grade 2. 
Although this comparison was not a primary endpoint, the 
diﬀ erence was signiﬁ cant. No validated method for 
measurement of quality of life in patients with vulval 
intraepithelial neoplasia was available at the start of the 
RT³VIN trial; therefore, we did not gather these data, other 
than for symptoms and adverse events. Such a method is 
now in development,25 and future trials should include 
quality-of-life data, along with a health-economic analysis.
In view of the complexity of setting up trials in 
uncommon disorders such as vulval intraepithelial 
neoplasia, future studies should allow new topical 
treatments to be assessed alongside existing ones in 
phase 3 assessments. Moreover, drug concentrations and 
dosing regimens for cidofovir and imiquimod could be 
optimised further. In our trial, cidofovir seemed to be 
better tolerated than imiquimod; therefore, in future 
studies, we might be able to augment complete responses 
Panel: Research in context
Systematic review
Current options for the management of vulval intraepithelial neoplasia are conservative, 
surgery, or an unlicensed alternative. As most women with vulval intraepithelial neoplasia 
have symptoms, conservative management is typically not appropriate. Many women 
wish to avoid surgery, which has substantial—generally longstanding—morbidity. 
A Cochrane systematic review of medical treatments for vulval intraepithelial neoplasia 
was done in 2011, which comprised three randomised controlled trials of imiquimod 
treatment for vulval intraepithelial neoplasia, but no published studies were included for 
cidofovir or other topical treatments.18 Findings of the three randomised trials showed a 
combined complete response in 36 (58%) of 62 patients assigned imiquimod compared 
with none of 42 allocated a placebo.19–21 Also, two retrospective studies including 
outcomes after treatment with imiquimod have been published, in which complete 
responses were reported in 47 (76%) of 62 patients and ten (31%) of 32 patients.22,23 
To date, no further randomised trials of topical treatment for vulval intraepithelial 
neoplasia have been completed. In addition to our cidofovir pilot study, in which a 
complete response was seen in four (40%) of ten women completing treatment,10 
one further trial of topical treatment with cidofovir for patients with vulval intraepithelial 
neoplasia has been completed—a phase 2a study in men and women with high-grade 
anal intraepithelial neoplasia and vulval intraepithelial neoplasia, all of whom were 
HIV-positive.24 Treatment was for 5 days, with a 9-day treatment gap, repeated for a total 
of six cycles. By intention-to-treat, a complete response was noted in ﬁ ve (15%) of 
33 patients and a partial response was recorded in 12 (36%). An update of the Cochrane 
review awaits publication of data from the RT3VIN trial.
Interpretation
Allowing for diﬀ erences in treatment regimens, the results of previous studies accord 
with those of the RT3VIN trial. Our study provides—to the best of our knowledge—the 
largest evidence-base so far from which an alternative to surgery can be oﬀ ered: either 
topical imiquimod or cidofovir. The RT3VIN trial was not powered to establish whether 
cidofovir or imiquimod was the most eﬀ ective treatment. However, complete responses 
in more than 45% of patients accord with available published work. Although more 
adverse events were noted with imiquimod, most were grade 2, and imiquimod is already 
licensed for use on the vulva, is readily available for prescription within hospitals as a 
topical treatment, and is much cheaper than cidofovir. Therefore, cidofovir could be 
reserved for patients who do not respond to imiquimod, although the numbers treated in 
this way within the RT³VIN trial were very small. 
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by increasing the dose of cidofovir in patients who do not 
respond initially. Alternatively, imiquimod could be tested 
at a lower dose to begin with, then raised if no response is 
recorded. Also, predictive markers for treatment response 
are needed urgently, because up to now, researchers have 
been unable to identify patients who are likely to respond 
to topical treatment. A comprehensive analysis of viral 
characteristics in the RT³VIN cohort is ongoing and 
might suggest potential predictive biomarkers. 
Comparing either cidofovir or imiquimod with excisional 
surgery will be fraught with diﬃ  culty: the outcomes that 
are the most important to women are not always easy to 
measure: methods to assess quality of life will emphasise 
symptoms that could be associated with one treatment or 
another. Complete regression is much more likely with 
surgery in the short term, and recurrence might depend 
on factors other than the treatment. Comparison of 
topical treatment with laser ablation should also be 
considered. HPV vaccination is expected to prevent most 
cases of vulval intraepithelial neoplasia in the future; 
therefore, obtaining funding for future trials could be 
challenging. In the meantime, a pragmatic approach will 
most likely have to be taken, whereby we explain to 
patients the potential beneﬁ ts and risks of the available 
treatment options and take their priorities for treatment 
into account in this diﬃ  cult management decision.
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